A343090 Stock Overview
Develops biological drugs with MoA to infectious diseases. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
HLB SCIENCE Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩2,220.00 |
52 Week High | ₩6,600.00 |
52 Week Low | ₩1,611.00 |
Beta | 0 |
1 Month Change | 16.78% |
3 Month Change | 12.12% |
1 Year Change | 7.51% |
3 Year Change | -78.45% |
5 Year Change | n/a |
Change since IPO | -48.67% |
Recent News & Updates
Recent updates
Shareholder Returns
A343090 | KR Biotechs | KR Market | |
---|---|---|---|
7D | 5.5% | 4.0% | 5.2% |
1Y | 7.5% | 13.2% | -4.3% |
Return vs Industry: A343090 underperformed the KR Biotechs industry which returned 13.2% over the past year.
Return vs Market: A343090 exceeded the KR Market which returned -4.3% over the past year.
Price Volatility
A343090 volatility | |
---|---|
A343090 Average Weekly Movement | 5.2% |
Biotechs Industry Average Movement | 8.9% |
Market Average Movement | 6.7% |
10% most volatile stocks in KR Market | 12.8% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A343090 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A343090's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | n/a | Yoon Jongsun | www.hlbscience.com |
HLB SCIENCE Inc. develops biological drugs with MoA to infectious diseases. Its pipeline includes DD-S052P, a candidate that exterminates germs and eliminates endotoxins; DD-A279, a new treatment to cure Alzheimer's Diseases by controlling LPS and Gram-negative bacteria; and DD-A514, a diagnosis kit for Alzheimer's diseases. The company was formerly known as Dandi Bio Science Co.,Ltd.
HLB SCIENCE Inc. Fundamentals Summary
A343090 fundamental statistics | |
---|---|
Market cap | ₩36.03b |
Earnings (TTM) | ₩0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A343090 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A343090 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩0 |
Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A343090 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/10 15:28 |
End of Day Share Price | 2025/01/10 00:00 |
Earnings | N/A |
Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HLB SCIENCE Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|